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Abstract
Aims This study aims to establish the feasibility, safety, and efficacy of outpatient intravenous (IV) diuretic treatment for the
management of decompensated heart failure (HF) for patients enrolled in the HeartFailure@Home service.
Methods and results We retrospectively analysed the clinical episodes of decompensated HF for patients enrolled in the
HeartFailure@Home service, managed by ambulatory IV diuretic treatment either at home or on a day-case unit. A control
group consisting of HF patients admitted to hospital for IV diuretics (standard-of-care) was also evaluated. In total, 203
episodes of decompensated HF (n = 154 patients) were evaluated. One hundred and fourteen episodes in 79 patients were
managed exclusively by the ambulatory IV diuretic service—78 (68.4%) on a day-case unit and 36 (31.6%) domiciliary;
84.1% of patient episodes under the HF@Home service were successfully managed entirely in an out-patient setting without
hospitalization. Eleven patients required admission in order to administer higher doses of IV diuretics than could be provided
in the ambulatory setting. During follow-up, there were 20 (17.5%) 30 day re-admissions with HF or death in the ambulatory IV
group and 29 (32.6%) in the standard-of-care arm (P = 0.02). There was no difference in 30 day HF readmissions between the
two groups (14.9% ambulatory vs. 13.5% inpatients, P = 0.8), but 30 day mortality was significantly lower in the ambulatory
group (3.5% vs. 21.3% inpatients, P < 0.001).
Conclusions Outpatient ambulatory management of decompensated HF with IV diuretics given either on a day case unit or
in a domiciliary setting is feasible, safe, and effective in selected patients with decompensated HF. This should be explored
further as a model in delivering HF services in the outpatient setting during COVID-19.
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Introduction
Heart failure (HF) is one of the commonest causes for
unplanned hospitalization.1,2 It accounts for approximately
2% of the total healthcare budget in the UK, and the majority
of these costs are attributable to hospitalization.3 Contempo-
rary management of a long-term condition ideally involves
an outpatient service equipped to manage episodes of dis-
ease instability without hospital admission.4 In cases where
self-care or supervised up-titration of oral diuretics have
proved ineffective, evidence is growing to support the safe
and effective administration of intravenous (IV) diuretics in
a community setting.5–7 Previous work has demonstrated
that community-based IV diuresis is cost-effective and
popular with patients.6 Despite these findings, adoption of
ambulatory IV diuretic therapy has not been widespread
and has yet to be formally recommended in either European
or North American guidelines. Presently, the practice remains
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limited to a small number of centres.5,8–12 Moreover, while
the use of IV diuretics in a day-unit setting for the treatment
of decompensated HF has been described, there is little
published on the utility and safety of domiciliary IV diuretics
(i.e. administered in the patient’s own home).6 Faced with
changes in healthcare delivery during the COVID-19
pandemic where there is a need to deliver effective services
while protecting our most vulnerable and highest risk
patients from nosocomial COVID-19 transmission, there is
an urgent need to explore alternative management strategies
that are at least as effective and safe as inpatient treatment.
Older patients in particular, who are at a higher risk of
COVID-19 complications, have the most to gain from a shift
in care from the inpatient to outpatient setting.13–17 Finally,
treating selected patients with decompensated HF outside
hospital has the potential to improve patient experience,
reduce in-patient bed days, and reduce cost.
The ‘HeartFailure@Home’ service was introduced at our
institution with the aim of providing ambulatory IV diuretics
(both domiciliary and on a day-unit) for selected patients
with decompensated HF. The aim of the current study was
to (i) examine the feasibility, safety, and efficacy of outpatient
IV diuretic treatment for the management of decompensated
HF and (ii) to examine healthcare utilization for patients
enrolled in the HeartFailure@Home service compared with
a consecutive sample of patients (controls) who received
inpatient IV diuretics (usual care).
Methods
Study design and setting
A retrospective single site observational analysis was per-
formed using data collected as part of routine clinical care
(undertaken in accordance with the STROBE statement for
reporting observational studies),18 for patients aged 18 and
over with decompensated HF undergoing intravenous (IV)
diuretic treatment in an ambulatory setting (day-unit
or domiciliary treatment) between 1 June 2015 and 13
September 2018. The control group consisted of patients
admitted to the hospital with an acute HF syndrome who
were treated with IV diuretics as per usual guideline recom-
mendations during the same time period.
Manchester Royal Infirmary (MRI) offers tertiary specialist
cardiology services to the Greater Manchester region, as well
as having a large Emergency Department and General
Internal Medicine Department. The hospital typically sees
550 admissions annually with a primary diagnosis of HF,
equating to approximately 8000 inpatient bed days. The
‘HeartFailure@Home’ ambulatory service was introduced in
2015 to offer ambulatory IV diuretics to selected patients with
decompensated HF, either in the patient’s home (home IV)
or on a day unit to avoid admission to hospital. Clinical care
is delivered by a multidisciplinary team of two consultant
cardiologists and a team of specialist nurses.
The HeartFailure@Home model used existing clinical
resources and services to facilitate the delivery of IV diuretics
in an outpatient setting. We used the IV adult community
therapy team (IV-ACT), who typically administer domiciliary
IV antibiotics, to facilitate IV diuresis in patient’s own homes,
and the hospital day unit (located within the hospital
premises) to deliver IV diuretics in an ambulatory setting.
Participants
Ambulatory intravenous diuretic patients
Adults with a primary diagnosis of decompensated HF,
refractory to escalating doses of oral diuretics and known
to the HF service, were considered for ambulatory IV
diuretics. Prior to referral to the HeartFailure@Home service,
all patients were assessed by a HF specialist and confirmed to
meet the inclusion/exclusion criteria shown in Table 1 and
Figure 1. Generally, higher risk patients on an active treat-
ment strategy were favoured towards care on the day unit
because this facilitated clinical review by an HF specialist if
required.
Intravenous diuretics were prescribed as a single daily
infusion of furosemide (up to a maximum of 240 mg, given
over a duration of up to 1 h, depending on dose). Patients
were advised to restrict their fluid intake, usually to a daily
limit of 1500 mL. General restriction of dietary sodium was
also advised, although not to a pre-specified limit. Depending
on the degree of volume overload, haemodynamic status,
Table 1 Inclusion and exclusion criteria for management by the
HeartFailure@Home service
HeartFailure@Home patient inclusion criteria
(1) Adult patients in the community with decompensated
chronic heart failure who have failed to respond to
increasing doses of oral diuretic treatment
(2) Inpatients with decompensated heart failure receiving IV
diuretics who were willing and able to complete their IV
diuretic treatment on an outpatient basis
HeartFailure@Home patient exclusion criteria
(3) Patients with haemodynamic instability or new oxygen
requirement
(4) Episode of decompensation deemed secondary to a new or
uncontrolled atrial arrhythmia
(5) Decompensated heart failure associated with acute kidney
injury
(6) Patients who require admission due to another acute medical
illness
(7) Patients with untreated severe valvular heart disease unless
already assigned to a palliative management strategy
(8) Patients unwilling to receive treatment as an outpatient
(9) Patients requiring additional functional or social support
which was not feasible to arrange in the community setting
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and renal dysfunction, patients were advised to either stop,
adjust, or continue their usual oral diuretics while receiving
IV furosemide. In cases where recompensation of HF was
not achieved due to inadequate diuresis at maximum diuretic
dose, and provided both renal function and haemodynamics
were satisfactory, adjunctive oral thiazide diuretic could be
added at the discretion of the physician. For patients
receiving IV diuretics at home, IV treatment was available
7 days per week. For patients receiving IV diuretics on the
day unit, IV treatment was only available during week days;
oral diuretics were given on weekend days.
For patients receiving home IV diuretics, treatment was
administered by a specialist nurse from the IV-ACT team.
During the daily visit, vital signs (heart rate, blood pressure,
oxygen saturation) and body weight were recorded, as well
as a subjective assessment of change in overall clinical status,
including severity of peripheral oedema. An intravenous
cannula was inserted to administer IV furosemide, if not
already present. Blood was taken daily for biochemistry
(‘renal profile’, including serum sodium, potassium, urea,
and creatinine, and ‘hepatic profile’, including serum alkaline
phosphatase, alanine transaminase, albumin, total protein,
and bilirubin); blood was taken for haematology (full blood
count) every 3 days. All of these tasks were within the usual
skillset of the IV-ACT specialist nurses, and as such, no further
specific clinical training was required for these nurses.
The aforementioned information (blood results, vital signs,
weight, subjective clinical assessment, and dose of diuretic
administered) was relayed to the specialist HF team in the
hospital electronically each day; further instructions,
including continuation, escalation, or discontinuation of IV
therapy, were then relayed back to the IV-ACT team for the
following day.
For the purpose of this evaluation, a treatment episode for
ambulatory IV patients began on the first day of IV diuretic
treatment and ended on the last day of IV diuretic treatment.
Figure 1 HeartFailure@Home pathway for ambulatory IV diuretics (domiciliary and day unit).
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Control group
A control group of ‘usual care’ patients admitted to hospital
with decompensated HF via the emergency department or
acute medical unit was also evaluated. Data for this group
were obtained by screening HF admission records for the
period between 20 June 2017 and 13 December 2018.
Patients with a primary (i.e. at admission) diagnosis and dis-
charge diagnosis of acute decompensated HF were included,
to capture a group of patients with fluid congestion due to
HF as their sole reason for hospitalization. All patients were
commenced on IV diuretics within 48 h of admission and
had no other identifiable acute illness. All patients were
reviewed by the HF service during their inpatient stay and
received HF follow-up on discharge; all patients were given
similar advice on fluid and salt restriction as for the ambula-
tory IV diuretic group. Patients with a new diagnosis of HF
were excluded, as were patients with clinical evidence of
significant pulmonary oedema or acute renal impairment at
initial presentation, patients with an arrhythmia that
contributed significantly to their hospitalization, e.g. atrial
fibrillation with rapid ventricular rate, those who underwent
invasive diagnostic or therapeutic procedures, cases requiring
ITU care for circulatory support or invasive/non-invasive
ventilation, cases where admission was complicated by
hospital acquired infection (HAI), or where the presence of
social factors impacted on discharge. Patients in the usual
care arm had not previously been assessed using the
HeartFailure@Home criteria as they were admitted via the
emergency department or acute medical unit and as such
had not previously received ambulatory IV diuretics.
Admission and discharge dates were used to establish start
and end dates of an episode. Cases where admission weight
was not recorded or where drug chart information was
incomplete or not available were excluded. Cases where
ambulatory diuretics were administered to facilitate early
discharge were excluded from both arms of the analysis.
Taking these criteria into account, we then included data from
a sample size of patients similar to that of the ambulatory IV
diuretic group.
Variables and data sources
Baseline demographic data were collected for all patients at
the time of their index referral to the HeartFailure@Home
service. Clinical records were reviewed for patients in the
usual care arm (Table 2). Data concerning dose and duration
of IV furosemide, whether the patient was prescribed their
usual oral diuretics or their treatment supplemented with a
thiazide diuretic, were recorded. Baseline weight, full blood
count, and renal profile were measured prior to commencing
IV diuretics. After commencing IV diuretics, clinical assess-
ment, which included an assessment of peripheral oedema,
measurement of blood pressure, pulse rate, oxygen satura-
tions, and renal profile were assessed daily by specialist
nurses, as described earlier. Body weight was monitored
routinely, except in instances where the patient was immo-
bile or nearing the end of life. Free text information was
categorized retrospectively at the time of data extraction.
Hospitalization data concerning length of stay, 30 day
readmissions, heart failure hospitalizations (HFH) in the
12 months before and after index treatment episode for
patients in both groups, and 12 month mortality were
recorded using electronic health records and local hospital
episodes statistics (HES) data.
Definitions
Uncomplicated HeartFailure@Home episode
This was defined as (i) re-compensation of a decompensated
patient, where treatment was delivered entirely in an
outpatient setting (admission avoidance).
Complicated HeartFailure@Home episode
Where treatment was complicated by (i) acute kidney
injury (AKI) stage 1, defined as increased serum creatinine
>1.5-fold two-fold from baseline,19 or (ii) where hospitaliza-
tion was necessitated prior to the end of that treatment
episode (either related to the episode of decompensation
that required a higher dose of diuretics than could be admin-
istered in an ambulatory setting, or due to alternative acute
medical problem).
Uncomplicated heart failure hospitalization in the control
group
This is defined as admission with subsequent
re-compensation and discharge from hospital, not compli-
cated by AKI.
Complicated heart failure hospitalization in the control
group
This is defined as admission where either the patients did not
recompensate, developed AKI ≥ stage 1or died.
Statistical analysis
Data were collected and managed on Microsoft Excel 2016.
Statistical analyses were performed using MATLAB version
R2019a. Data are presented as mean (range), median
(range/IQR), or N (%) as appropriate. Categorical data were
compared using Fisher’s exact test, and continuous data
were compared using Student’s t-test in the case of normal
distribution or Mann–Whitney U test in non-normal distribu-
tion. A P value <0.05 was considered statistically significant:
MD = mean difference, 95% CI = 95% confidence intervals,
IQR = interquartile range, SD = standard deviation.
4 F.Z. Ahmed et al.
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In total, 203 episodes of decompensated HF (n = 154
patients) were evaluated. One hundred and fourteen
episodes of decompensated HF, occurring in 79 patients,
were managed by the ambulatory HeartFailure@Home
service. All patients were reviewed by a HF specialist and
trialed on increased oral diuretics before being referred to
either arm of the service and commencing IV diuretics;
78/114 (68.4%) episodes were managed on the day-case unit;
36/114 (31.6%) were managed in the patient’s own home.
Twenty patients had more than one treatment episode, and
six patients used both the day unit and domiciliary arms of
the service during follow-up. In the control group, 89 episodes
of decompensated HF (n = 75 patients) were managed
according to standard of care with inpatient IV diuretics.
Characteristics
Baseline demographic data are presented in Table 2. This
represents three heterogeneous groups [the ambulatory IV
diuretic group, which was subdivided into groups of patients
managed on the day unit or home IV group, and the usual
care group (inpatients)]. Ambulatory IV diuretic patients
(both day unit and home IV) were older than those
managed as inpatients (77.1 vs. 71.2 years; MD = 5.9, 95%
CI = 1.84–9.90, P = 0.005). Although the sex distribution
was similar between all ambulatory IV patients and inpa-
tients, a higher proportion of day unit patients were male
(64.2% day unit vs. 43.8% home IV, P = 0.08). Significantly
more patients in the day unit group had CKD ≥ stage 3 at
baseline compared with both home IV patients (P < 0.001)
and inpatients (P = 0.003).
Significantly more patients in the ambulatory group had a
history of recent HF hospitalization (50.6% vs. 33.3%,
P = 0.03). In the 12 months prior to their enrolment into
the HeartFailure@Home service, 40 patients had been
hospitalized on a total of 79 occasions with a primary diagno-
sis of HF, with nine patients (11.4%) hospitalized on three or
more occasions during that period. A higher proportion of
patients in the ambulatory IV diuretic were established on a
palliative management pathway (commenced either prior to
or during the treatment episode) compared with inpatients
(31.6% vs. 6.7%; P < 0.001).
Diuretic treatment
Median duration of IV diuretic treatment was similar
across both the inpatient group and ambulatory group
[7 (IQR 5.75) vs. 6 (IQR 10) days, P = 0.3] (Table 2).
Concomitant use of thiazides was significantly higher
among inpatients (36.0% vs. 14.1%; P < 0.01), as was mean
weight loss from start to end of treatment (4.9 vs. 3.1 kg,
MD = 1.8, 95% CI = 0.2–3.4, P = 0.03). There was no
difference in mean weight loss per episode between home
IV and day-unit cases (3.1 kg).
Treatment outcomes
Similar proportions of patients, managed by the ambulatory
service and as inpatients, had an uncomplicated treatment
episode (84.1% vs. 82.1%; P = 0.84). AKI occurred more fre-
quently in the standard of care group (AKI 8.3%, P = 0.03).
Episode outcomes (uncomplicated vs. complicated episode
data) were evaluated for 172 (84.7%) episodes [84/89 (94.4%)
standard of care and 88/114 (77.2%) HeartFailure@Home
cases] (Table 3). Of these, 74 episodes (84.1%) were success-
fully managed by the HeartFailure@Home service and
re-compensated without hospitalization at any point during
the treatment episode. Eleven patients (14.1%) in the day
unit arm and two patients (5.6%) in the home IV arm re-
quired hospitalization. The majority of these were admitted
in order to administer higher doses of intravenous diuretics
than could be provided in an outpatient setting according
to the protocol in place at the time (over 240 mg Furose-
mide once daily). One patient (1.2%) in the day unit arm
developed AKI stage 1 requiring hospitalization during the
course of treatment and was admitted for observation while
treatment continued. There were no instances of AKI in the
home IV arm.
Twenty (25.3%) patients used the HeartFailure@Home
service on more than one occasion. Of these, seven (35%)
patients used the service more than twice. Three patients
used the service on five occasions.
Heart failure hospitalization and death after
index treatment episode
During follow-up, patients were either readmitted with a
primary diagnosis of heart failure or died within 30 days
following 20 (17.5%) episodes in the ambulatory IV diuretic
group and 29 (32.6%) episodes in the standard of care arm
(P = 0.02). At 12 months, this increased to 61 (53.5%)
episodes in the ambulatory IV arm and 60 (67.4.%) episodes
for the inpatient group (P = 0.06). Three of the four patients
in the ambulatory care arm who died within 30 days of treat-
ment were on an established palliative care plan.
There was no difference in 30 day HF readmissions
between the two groups (14.9% ambulatory vs. 13.5%
inpatients, P = 0.8), but 30 day mortality was significantly
lower in the ambulatory group (3.5% vs. 21.3% inpatients,
P < 0.001) (Table 4).
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Discussion
In this study, the largest UK report on ambulatory IV di-
uretics with data spanning almost 3 years, we demon-
strate that ambulatory IV diuretic treatment for
decompensated HF affords a safe and effective alternative
to hospitalization. The majority of ambulatory IV patients
had an uncomplicated treatment episode, despite pa-
tients in our study being more elderly, with a high preva-
lence of CKD and other co-morbid conditions. In
particular, the incidence of AKI was lower in the ambula-
tory IV diuretic group compared with those managed as
inpatients, and 30 day outcomes (re-admission with a pri-
mary diagnosis of HF, or death) favoured those managed
by the HeartFailure@Home service. In addition, despite
the HeartFailure@Home patients being older, with a
higher proportion established on a palliative management
strategy (31.6%), rates of HF hospitalization or death were
significantly lower at 30 days compared with patients
treated as inpatients.
To date, the majority of data concerning ambulatory IV
diuretics has focused on admission avoidance through use
of day-units (Supporting Information, Table S1).20 The cur-
rent study is novel in that our service configuration
allowed patients to be stratified to either ambulatory
treatment in a day-unit setting, or domiciliary treatment;
almost one-third of episodes were managed in the pa-
tient’s own home. Renal function, relative haemodynamic
stability, frailty, where the patient lived, and patient
choice were factors considered when determining place
of treatment. Domiciliary IV diuretic treatment was asso-
ciated with the lowest rates of conversion to inpatient
treatment (5.6%), and there were no instances of AKI in
this group.
Despite significant improvements in drugs and thera-
peutic devices used to treat HF, the number of patients be-
ing hospitalized due to HF continues to increase, in part
due to the rising prevalence of cardiovascular disease
and an aging population. Many patients are resistant to es-
calating doses of oral diuretics, and the only way to man-
age these cases has been to admit to hospital for IV
diuretics. Once commenced on IV diuretic treatment, pa-
tients typically remain in hospital until they have
recompensated and have been re-established on oral di-
uretics. Moreover, in many instances, discharge does not
swiftly follow recompensation. A lack of physical activity
during hospitalization can lead to deconditioning, requir-
ing physical therapy, which may delay discharge.21
Hospitalization of HF patients, who are typically older
with multi-morbidity, is not benign—it is associated with
significant morbidity and mortality.22 Furthermore, HF pa-
tients represent an at-risk group of patients from mortal-
ity particularly if infected with COVID-19. There has been
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tal-acquired COVID-19 infection of those most vulnerable to
adverse outcomes, such as elderly patients with cardiovascu-
lar diseases. Ambulatory HF diuretic services represent an al-
ternative to admission, designed to deliver care in an
outpatient or home setting.
While treatment for domiciliary (home IV) patients is
supervised by hospital-based HF teams, there are relatively
fewer in-person assessments undertaken directly by the HF
team. Instead, there is a reliance on virtual specialist review,
performed using monitored physiological parameters
communicated electronically by community-based services
(IV-ACT). It is unclear whether this multi-agency approach to
delivering care in the community, with daily remote HF team
review of patient data and a standard operating policy
outlining acceptable physiological parameters, was in part
responsible for the lower number of adverse outcomes
observed in the ambulatory IV group. Multi-agency involve-
ment, and the fact that the care plan/medical records for
home IV patients were held by the patient, may have
potentially led to an increase in the amount of
self-management advice, both passive and active.
The HeartFailure@Home clinical pathway primarily man-
aged older patients, who typically have a higher burden of
co-morbidity than younger patients and are at higher risk of
HF decompensation. This is of particular significance, as the
mean age reported in the current evaluation is higher than
that reported in previous studies evaluating the efficacy of
IV diuretics in an ambulatory cohort (Supporting Information,
Table S1).5,8–12,23–25
A history of HF hospitalization was observed more
frequently among the ambulatory IV diuretics group. Prior
to initial enrolment on the HeartFailure@Home programme,
the majority of patients (50.6%) had been hospitalized at
least once with HF in the preceding 12 months, accounting
for 1008 inpatient bed days. After enrolment in the
HeartFailure@Home programme, 20 (25.6%) patients used
the HeartFailure@Home service on two or more occasions,
highlighting that this is a population of patients who decom-
pensate frequently. Six (7.7%) patients used both arms of
the service, highlighting the ability to tailor treatment
according to clinical need and patient choice.
Over 30% of patients in the HeartFailure@Home
programme were on a palliative management strategy. The
higher use of palliative management strategies may have
been influenced by a number of factors including higher
incidence of previous HF admissions, older age, familiarity
with patient’s prognosis, and increased consultant cardiolo-
gist input. When the fact that hospitalization is unlikely to
improve the prognosis is recognized, then provision of care
outside the hospital environment may represent a more
patient-centric model and inadvertently improve care. The
use of outpatient IV diuresis as part of an individualized
end-of-life care plan has the potential to rapidly relieve
distressing symptoms in a more comfortable setting.
Provision of hospice services and subcutaneous furosemide
is heterogenous, and perhaps, this model of care can fill a
gap in care provision. This requires further evaluation and a
separate body of work in conjunction with palliative care
services; however, work so far has been promising.
Nineteen of 79 (24.1%) patients managed by the
HeartFailure@Home service were non-white ethnic minori-
ties. Although some patients did not speak English, this was
not a barrier to delivering care, either in a domiciliary setting
or on the day unit. Perceived barriers to treatment were
easily circumvented, and treatment in an ambulatory setting
may have provided greater patient autonomy (e.g. residing in
their home environment with unfettered access to usual
support networks, uninterrupted observation of religious
practices) (Figure 2).
The main clinical concern regarding safety of the
HeartFailure@Home service was that IV diuretic therapy
could precipitate hypotension and/or renal dysfunction, a
particular concern in a domiciliary setting. Thirteen (11.4%)
patient episodes on the clinical pathway required hospitaliza-
tion, mainly for higher dose diuresis (one patient for
hyponatraemia and one due to transport issues). No patient
required hospitalization due to hypotension, and only one
patient was hospitalized due to AKI. There is a paucity of
published literature to compare our results with other
centres. However, the admission rate for the
HeartFailure@Home cohort is significantly lower than has
been reported in previous studies.5,7,26
Limitations
As a non-randomized study the analysis is subject to the usual
bias associated with observational data, and as described
earlier, there were significant differences in the baseline
characteristics between the groups. Additionally, the group
Table 4 Follow-up data
In patients
HeartFailure@Home
All Day unit Home IV
HFH or death within 30
days of end of episode
29/89 (32.6%, 12 HFH,
19 deaths)
20/114 (17.5%) 15/78 (19.2%, 14 HFH,
2 deaths)
5/36 (13.9%, 3 HFH,
2 deaths)
HFH or death within 12
months of end of episode
60/89 (67.4%, 38 HFH,
34 deaths)
61/114 (53.5%) 45/78 (57.7%, 25 HFH,
28 deaths)
16/36 (44.4%, 9 HFH,
11 deaths)
HFH, heart failure hospitalization; HF@H, Heart Failure at Home service.
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sizes are small, limiting the strength of comparison between
groups, and in particular interpretation of the outcome
measures that we have reported should take this into
account. Furthermore, the geographical area covered by the
HeartFailure@Home service is relatively urban; thus, this
model of care may not be generalizable to more rural areas
or other healthcare systems. We report outcomes for a lower
proportion of the HeartFailure@Home group (88/114
episodes; 77.2%) compared with the usual care group
(84/89 episodes; 94.4%), in part due to the fact that
treatment records for domiciliary and day unit patients
were retained in the respective places of care, sometimes
by the patient; this may introduce bias towards the
HeartFailure@Home group by underestimating the number
of complicated episodes in this group. Conversely, patients
hospitalized with HF who experienced a HAI were excluded
from this study in an attempt to closely match the two pop-
ulations; had these patients been included, additional benefit
from ambulatory IV diuretic treatment may have been more
apparent. The relative impact of social circumstances on
delays in discharge contributing increased length of stay
was not examined. Finally, following the completion of domi-
ciliary IV diuretic therapy, the home IV team would routinely
visit the patient in their own home at ≤1 week to perform a
repeat assessment of fluid status and check renal profile;
the relative significance of this visit on downstream HFH is
unclear and should be explored in future studies to assess
the impact of post-treatment domiciliary follow-up on
subsequent HFH.
Conclusions
Outpatient management of decompensated HF with IV
diuretics is feasible, effective, and sustainable for patients
of all ages. The HeartFailure@Home model of care has been
achieved without specific additional funding or resource. A
formal economic evaluation could provide a strong argument
for nationwide service reconfiguration.
Figure 2 Potential beneficiaries of the HeartFailure@Home Service. Outlines the individuals/organizations who potentially stand to benefit from the
HeartFailure@Home service. Crucially, the patient has the most to gain; they can remain in their own home for the duration of their treatment,
avoiding exposure to hospital-related complications such as infections, thrombosis, and functional decline. Care is overseen (virtually or in-person)
by an HF specialist.
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